Database Query Results : Anthocyanins, ,

ACNs, Anthocyanins: Click to Expand ⟱
Features:

Anthocyanins — Anthocyanins (ACNs) are a structurally diverse class of water-soluble flavonoid pigments (glycosylated anthocyanidins) abundant in berries, purple/red grapes, cherries, red cabbage, and other deeply colored plants. They function as pleiotropic redox- and inflammation-modulating polyphenols with context-dependent signaling effects that can shift from antioxidant/anti-inflammatory tone at nutritionally relevant exposures to stress-signaling/pro-apoptotic effects in tumor models at higher concentrations. Classification: dietary polyphenols (flavonoids; anthocyanidin O-glycosides). Standard abbreviations: ACNs; often specified as C3G (cyanidin-3-O-glucoside) or as “total anthocyanins.” A key translation nuance is that circulating parent ACNs are typically low and transient, while phase-II conjugates and gut microbiota–derived phenolic acids (e.g., protocatechuic acid from cyanidin glycosides) plausibly mediate a meaningful fraction of systemic biology.

Primary mechanisms (ranked):

  1. Inflammation attenuation via NF-κB pathway suppression and downstream cytokines/COX-2/iNOS modulation
  2. Growth/survival signaling downshift (PI3K–Akt–mTOR and intersecting MAPK nodes; context- and model-dependent)
  3. Redox modulation (biphasic): antioxidant tone and inflammatory redox dampening at low exposure; pro-oxidant stress signaling at high concentration in tumor models (secondary)
  4. Mitochondria-linked intrinsic apoptosis and cell-cycle checkpoint control (often downstream of NF-κB/Akt/redox)
  5. Anti-invasive/anti-metastatic remodeling (EMT programs, MMPs, adhesion/invasion)
  6. Anti-angiogenic signaling (VEGF axis; endothelial migration/tube formation)
  7. Metabolic reprogramming pressure (HIF-1α/glycolysis programs; secondary, model-dependent)
  8. Microbiome–host signaling (barrier function, metabolite signaling, bile acid/SCFA context; indirect systemic mechanism)
  9. NRF2 antioxidant response activation in normal tissues with mixed implications in NRF2-addicted tumors (secondary)

Bioavailability / PK relevance: Oral bioavailability of intact parent anthocyanins is generally modest with rapid appearance and clearance; extensive phase-II metabolism (glucuronidation/sulfation/methylation) and prominent gut microbiota catabolism generate phenolic acid metabolites that may dominate systemic exposure. Local gastrointestinal exposures can be substantially higher than plasma levels, making “GI-local” mechanisms more plausible than “systemic parent-compound” mechanisms for many endpoints.

In-vitro vs systemic exposure relevance: Many anticancer in-vitro studies use ~10–100+ µM parent anthocyanins/extract equivalents, which often exceed achievable circulating parent anthocyanin concentrations after dietary intake; therefore, mechanistic claims that require high micromolar parent exposure should be treated as (high concentration only) unless supported by metabolite biology or GI-local relevance.

Clinical evidence status: Human evidence is strongest for cardiometabolic and inflammation-related biomarkers (multiple RCTs/meta-analyses). For cancer, evidence is predominantly preclinical and epidemiologic/biomarker-level in humans; there is no established oncology indication or regulatory approval as an anticancer drug. For cognition/brain aging, small RCTs with anthocyanin-rich foods/supplements show signal in select domains, but overall evidence remains exploratory.

"Anthocyanins are a class of water‐soluble flavonoids, which show a range of pharmacological effects, such as prevention of cardiovascular disease, obesity control and antitumour activity. Their potential antitumour effects are reported to be based on a wide variety of biological activities including antioxidant; anti‐inflammation; anti‐mutagenesis; induction of differentiation; inhibiting proliferation by modulating signal transduction pathways, inducing cell cycle arrest and stimulating apoptosis or autophagy of cancer cells; anti‐invasion; anti‐metastasis; reversing drug resistance of cancer cells and increasing their sensitivity to chemotherapy."
Anthocyanins are flavonoid pigments with multi-target pleiotropic effects in cancer models, primarily through modulation of ROS balance, NF-κB signaling, PI3K/Akt/mTOR inhibition, apoptosis induction, and anti-angiogenic activity. Their effects are often context-dependent and dose-dependent: low physiologic exposures tend to support antioxidant and anti-inflammatory tone, whereas higher concentrations in vitro can induce oxidative stress and apoptosis in tumor cells. They also influence tumor microenvironment dynamics including VEGF signaling, MMP activity, and inflammatory cytokines. Bioavailability is modest, and metabolites (phenolic acids) likely contribute significantly to biological effects. Evidence in humans remains supportive but not definitive.
• Anthocyanins are a class of water-soluble flavonoid pigments responsible for the red, purple, and blue hues in many fruits, vegetables, and flowers (e.g., berries, red grapes, and eggplants).
• Anthocyanins can effectively scavenge free radicals and reduce oxidative stress, thereby protecting cellular components like DNA, lipids, and proteins from oxidative damage—a factor linked to carcinogenesis.
• Their antioxidant capacity helps in neutralizing reactive oxygen species (ROS), which can otherwise promote mutations and tumor initiation.
• Anthocyanins have been shown to inhibit pro-inflammatory cytokines (e.g., TNF-α, IL-6) and enzymes (e.g., COX-2), reducing the inflammatory signals associated with cancer progression.
• They may modulate pathways such as NF-κB, MAPK, and PI3K/Akt, contributing to the downregulation of genes involved in survival and proliferation of cancer cells.
• Anthocyanins have been found to inhibit the formation of new blood vessels (angiogenesis) essential for tumor growth and metastatic spread.

Anthocyanins: ranked cancer-relevant pathway effects

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NF-κB inflammatory transcription NF-κB ↓; IL-6/TNF-α/COX-2/iNOS ↓ (model-dependent) Inflammatory tone ↓; endothelial/immune activation ↓ (context-dependent) R, G Anti-inflammatory, anti-survival signaling pressure Often the most reproducible “systems-level” effect across anthocyanin mixtures; frequently upstream of apoptosis, invasion, and angiogenesis programs.
2 PI3K–Akt–mTOR growth and survival Akt ↓; mTOR ↓; survival signaling ↓ (model-dependent) Metabolic stress signaling ↔/↓ (context-dependent) R, G Anti-proliferative signaling shift Commonly reported in breast/colon/liver/prostate models; “extract” studies can reflect multi-node inhibition rather than a single target.
3 Mitochondria and intrinsic apoptosis MOMP ↑; caspases ↑; Bcl-2 family shift toward apoptosis (model-dependent) Pro-apoptotic signaling ↔/↓ at nutritional exposure; stress resistance ↑ (context-dependent) R, G Apoptosis induction / survival loss Frequently downstream of redox or Akt/NF-κB suppression; strong in vitro, but dose-exposure realism is the key constraint.
4 ROS balance ROS ↑ (high concentration only) or ROS ↓ (context-dependent) ROS ↓; lipid peroxidation markers ↓ (often) P, R Redox buffering or stress signaling Biphasic: antioxidant/anti-inflammatory at low exposure; pro-oxidant stress signaling at higher concentrations in tumor models is reported but may be exposure-limited systemically.
5 EMT and invasion programs EMT ↓; migration/invasion ↓ (model-dependent) Tissue remodeling ↔ (context-dependent) G Anti-invasive phenotype pressure Often linked to NF-κB, TGF-β/Smad, and MMP suppression; more consistent for “behavioral endpoints” than for a single molecular node.
6 MMPs and extracellular matrix degradation MMP-2 ↓; MMP-9 ↓ (model-dependent) ECM turnover ↔ (context-dependent) G Reduced metastatic potential Pairs mechanistically with EMT suppression and inflammatory signaling downshift.
7 Angiogenesis and VEGF axis VEGF signaling ↓; endothelial support ↓ (model-dependent) Endothelial activation ↓ (context-dependent) G Anti-angiogenic pressure Typically secondary to NF-κB/HIF-1α modulation; most convincing in models rather than as a clinically validated endpoint.
8 Cell-cycle checkpoints G1/S or G2/M arrest ↑ (model-dependent) Cell-cycle stress ↔/↓ (context-dependent) R, G Proliferation restraint Often emerges as an integrated phenotype downstream of Akt/NF-κB redox signaling rather than a direct CDK inhibitor effect.
9 HIF-1α and glycolysis programs HIF-1α ↓; glycolysis gene program ↓ (model-dependent) Metabolic flexibility ↔ (context-dependent) G Metabolic reprogramming pressure Best treated as secondary unless a specific anthocyanin/metabolite mechanism is shown at realistic exposure.
10 NRF2 antioxidant response NRF2 ↔/↑/↓ (model-dependent) NRF2 ↑; cytoprotective enzymes ↑ (often) R, G Stress-response adaptation Potential benefit in normal-tissue protection; theoretical caution if a tumor is NRF2-addicted or relies on high antioxidant capacity.
11 Ca²⁺ signaling Ca²⁺ flux ↔/disrupted (model-dependent) Excitotoxic stress signaling ↓ (context-dependent) P, R Signal modulation under stress Reported in subsets of models; generally not treated as a primary axis unless tied to a clear phenotype (e.g., apoptosis, barrier function).
12 Clinical Translation Constraint Systemic parent exposure often low; heterogeneity of mixtures; biomarker-to-outcome gap Generally favorable food safety profile — Limits on “drug-like” claims Interpretation should weight GI-local effects, metabolite biology, and RCT biomarker outcomes higher than high-µM in-vitro parent-compound findings.

TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr



Anthocyanins and Alzheimer’s disease — Anthocyanin-rich foods/supplements have small-human-trial signals suggesting modest improvements in selected cognitive domains and/or brain function proxies in at-risk or impaired cohorts, plausibly mediated through vascular/inflammatory tone, oxidative stress buffering, and microbiome–metabolite signaling (rather than sustained high circulating parent anthocyanins). Overall, evidence remains exploratory and heterogeneous across preparations, doses, and endpoints.

Clinical evidence status: Small RCTs/pilot trials (food-based and some purified preparations) with mixed but promising signals; not an established disease-modifying therapy.

Anthocyanins: non-cancer mechanisms relevant to Alzheimer’s disease

Rank Pathway / Axis Modulation Primary Effect Notes / Interpretation
1 Neuroinflammation ↓ Lower inflammatory signaling tone Human biomarker/meta-analytic evidence supports anti-inflammatory effects in non-cancer contexts; translation to dementia outcomes remains unproven.
2 Oxidative stress and redox homeostasis ↓ Reduced oxidative burden; cytoprotection Mechanistically consistent with polyphenol biology; likely mediated substantially by metabolites rather than sustained parent anthocyanins.
3 Neurovascular and endothelial function ↑ Support for perfusion/vascular tone Common mechanistic bridge between cardiometabolic benefits and brain aging hypotheses; endpoints vary by trial design.
4 Gut microbiota–metabolite axis ↔ Metabolite signaling, barrier support Growing evidence that gut-derived phenolic acids contribute to systemic and possibly neuroactive effects; causal mapping in humans is still developing.
5 Aβ processing and proteostasis ↓ Potential reduction in amyloidogenic pressure Preclinical and mechanistic papers exist; human evidence for amyloid/tau modification is limited and not definitive.
6 Clinical Translation Constraint — Heterogeneous preparations and endpoints Signals exist in small RCTs/pilots, but dose standardization, metabolite exposure mapping, and durable clinical outcomes remain the key gaps.


Scientific Papers found: Click to Expand⟱
1094- ACNs,    Anthocyanidins inhibit epithelial-mesenchymal transition through a TGF-β/Smad2 signaling pathway in glioblastoma cells: Anthocyanidins inhibit TGF-β-mediated EMT.
- in-vitro, GBM, U87MG
EMT↓,
1161- ACNs,  immuno,    Bilberry anthocyanin extracts enhance anti-PD-L1 efficiency by modulating gut microbiota
- in-vivo, Colon, MC38
GutMicro↑,
3864- ACNs,    Anthocyanins Potentially Contribute to Defense against Alzheimer’s Disease
- Review, AD, NA
*antiOx↑, *Aβ↓, *ROS↓, *cognitive↑, *APP↓, *BBB↑, *Ca+2↓, *ATP↑, *BACE↓, *p‑NF-kB↓, *TNF-α↓, *iNOS↓,
3865- ACNs,    Consumption of anthocyanin-rich cherry juice for 12 weeks improves memory and cognition in older adults with mild-to-moderate dementia
- Human, AD, NA
*memory↑, *BP↓, *cognitive↑,
3968- ACNs,    Enhanced Neuronal Activation with Blueberry Supplementation in Mild Cognitive Impairment
- Human, AD, NA
*BOLD↑, *cognitive?, *eff↑,
3969- ACNs,    Blueberry Supplementation in Midlife for Dementia Risk Reduction
- Human, AD, NA
*memory↑, *cognitive↑, *ROS↓,
3970- ACNs,    Anthocyanin-rich blueberry extracts and anthocyanin metabolite protocatechuic acid promote autophagy-lysosomal pathway and alleviate neurons damage in in vivo and in vitro models of Alzheimer's disease
- in-vivo, AD, NA
*cognitive↑, *LDH↓, *ROS↓, *neuroP↑,
3971- ACNs,    Blueberry Supplementation Improves Memory in Older Adults
- Human, AD, NA
*antiOx↑, *Inflam↓, *memory↑, *neuroP↑, *cognitive↑, *Mood↑, *glucose↓,
3972- ACNs,    Recent Research on the Health Benefits of Blueberries and Their Anthocyanins
- Review, AD, NA - Review, Park, NA
*cardioP↑, *neuroP↑, *Inflam↓, *antiOx↓, *GutMicro↑, *Half-Life↑, *LDL↓, *adiP↓, *HDL↑, *CRP↓, *IL1β↓, *Risk↓, *Risk↓, *cognitive↑, *memory↑, *other↑, *BOLD↑, *NO↓, *MDA↓, *GSH↑, *VitC↑, *SOD↑, *GPx↑, *eff↓, *eff↓, *eff↓, *eff↝, *Risk↓,
3973- ACNs,    Saskatoon and wild blueberries have higher anthocyanin contents than other Manitoba berries
- Analysis, AD, NA
eff↑,
4163- ACNs,  Flav,    Dietary levels of pure flavonoids improve spatial memory performance and increase hippocampal brain-derived neurotrophic factor
- in-vivo, AD, NA
memory↑, *BDNF↑, *cognitive↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 11

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,  

Functional Outcomes ⓘ

memory↑, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 2,   GPx↑, 1,   GSH↑, 1,   HDL↑, 1,   MDA↓, 1,   ROS↓, 3,   SOD↑, 1,   VitC↑, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,  

Core Metabolism/Glycolysis ⓘ

adiP↓, 1,   glucose↓, 1,   LDH↓, 1,   LDL↓, 1,  

Cell Death ⓘ

iNOS↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Migration ⓘ

APP↓, 1,   Ca+2↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

CRP↓, 1,   IL1β↓, 1,   Inflam↓, 2,   p‑NF-kB↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

BDNF↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↓, 3,   eff↑, 1,   eff↝, 1,   Half-Life↑, 1,  

Clinical Biomarkers ⓘ

BP↓, 1,   CRP↓, 1,   GutMicro↑, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

BOLD↑, 2,   cardioP↑, 1,   cognitive?, 1,   cognitive↑, 7,   memory↑, 4,   Mood↑, 1,   neuroP↑, 3,   Risk↓, 3,  
Total Targets: 44

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:31  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page